Cargando…

Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?

Detalles Bibliográficos
Autores principales:	Gianfrancesco, Milena A, Robinson, Philip C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906652/ https://www.ncbi.nlm.nih.gov/pubmed/33655223 http://dx.doi.org/10.1016/S2665-9913(21)00008-4

Ejemplares similares

COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020)

Cancer and COVID-19: what do we really know?
por: Poortmans, Philip M, et al.
Publicado: (2020)

Myeloid leukemia: are we getting better?()
por: Hamerschlak, Nelson
Publicado: (2015)

Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes
por: Liew, David F L, et al.
Publicado: (2022)

Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases
por: Antonelli, Alessandro, et al.
Publicado: (2021)

COVID-19 in patients with rheumatic disease: finally, a denominator
por: Wallace, Daniel J
Publicado: (2021)

Open Questions: We don’t really know anything, do we? Open questions in sensory biology
por: Johnsen, Sönke
Publicado: (2017)

Public communication about public health where we really need to go
por: Ranney, Megan L., et al.
Publicado: (2022)

Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases
por: Felten, Renaud, et al.
Publicado: (2021)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
por: Sen, Parikshit, et al.
Publicado: (2023)

How can we get sober from the influence of the alcohol industry?
por: Monteiro, Maristela G, et al.
Publicado: (2022)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

Understanding COVID-19: what does viral RNA load really mean?
por: Joynt, Gavin M, et al.
Publicado: (2020)

Long COVID in inflammatory rheumatic diseases—what's in a name?
por: Calabrese, Leonard H
Publicado: (2023)

First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea
por: Schreiber, Karen, et al.
Publicado: (2021)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
por: Barbhaiya, Medha, et al.
Publicado: (2022)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

COVID-19 and liver disease: where are we now?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Racial and ethnic differences in COVID-19 outcomes: a call to action
por: Robinson, Philip C, et al.
Publicado: (2022)

Are We Really Getting Conservation So Badly Wrong?
por: MacKinnon, Kathy
Publicado: (2011)

Importance of nociplastic pain in patients with rheumatic diseases
por: Alcántara Montero, Antonio
Publicado: (2023)

Preoperative anxiety: what are we really doing?
por: Buonanno, Pasquale, et al.
Publicado: (2021)

ECMO for severe ARDS associated with COVID-19: now we know we can, but should we?
por: Shekar, Kiran, et al.
Publicado: (2020)

A new gambler at the table of management of COVID-19 associated acute respiratory failure. Changing position to do it better?
por: Crimi, C., et al.
Publicado: (2023)

Consumer genomics will change your life, whether you get tested or not
por: Khan, Razib, et al.
Publicado: (2018)

COVID-19 vaccine: what are we doing and what should we do?
por: Candelli, Marcello
Publicado: (2022)

Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries
por: El Kibbi, Lina, et al.
Publicado: (2022)

Open questions: how to get developmental biology into shape?
por: Saunders, Timothy E., et al.
Publicado: (2019)

COVID-19 herd immunity: where are we?
por: Fontanet, Arnaud, et al.
Publicado: (2020)

Vitamin D for COVID-19: where are we now?
por: Martineau, Adrian R., et al.
Publicado: (2022)

Getting the upper hand in ALS
por: Svendsen, Clive N.
Publicado: (2022)

Offline: COVID-19—what we can expect to come
por: Horton, Richard
Publicado: (2020)

The COVID-19 pandemic in the USA: what might we expect?
por: Chowell, Gerardo, et al.
Publicado: (2020)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Rheumatology congresses post COVID-19: we cannot regress
por: Nordberg, Lena Bugge, et al.
Publicado: (2023)

COVID-19 and clean air: an opportunity for radical change
por: Landrigan, Philip J, et al.
Publicado: (2020)

Statistics on steroids: How recognizing competing risks gets us closer to the truth about COVID-19-associated VAP
por: Shorr, Andrew F., et al.
Publicado: (2022)

Divergent effects of acute versus chronic glucocorticoids in COVID-19
por: Robinson, Philip C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_urdn24uinbukp779akh0pbamrb